Use of il-13 receptor subunit alpha 2 as an anti-cancer vaccine
CA 2480008 C · Owner: Mintz, Akiva · Inventors: Christensen, Neil; Mintz, Akiva; Debinski, Waldemar
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for stimulating an immune response against IL-12R.alpha.2 in a subject having or at risk for developing a disease having cells expressing IL- 13R.alpha.2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13R.alpha.2 in the subject. A composition for stimulating an immune response agaist IL- 13R.alpha.2 in a subject having or at risk for developing a disease having cells expressing IL-13R.alpha.2 includes an isolated agent that can stimulate immune response against IL-13.alpha.2.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 22, 2002 and granted October 6, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 22, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 22, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.